Costco (NASDAQ:COST) is preparing to introduce a new weight-loss program in partnership with Sesame. This will allow particular patients to acquire the weight-loss drug Ozempic from the retailer’s pharmacy partner. The service enables customers to enroll in a weight-loss subscription service costing $179 every three months.
The weight-loss service provided by Sesame incorporates consultations and support from clinicians. This may include prescribing patients Ozempic if it is deemed appropriate. This current initiative expands on an ongoing relationship between Costco and Sesame that started the previous year.
Sesame’s co-founder and President, Michael Botta, discussed the Costco weight-loss program. He said, “It wasn’t what we initially thought would make sense to offer for Costco members who were coming to Sesame […] But we realized pretty quickly, just by looking at what people were curious about, that there was a clear unmet need here.”
Aside from Ozempic, patients engaged in the Costco weight-loss program can access other weight management drugs. These include Wegovy, Mounjaro, and Zepbound. As of Wednesday morning, COST stock has seen a decrease by 1.3%.
For investors interested in the most recent stock market narratives, more information is available on shares of Intel (NASDAQ:INTC) stock, Vanda Pharmaceuticals (NASDAQ:VNDA) stock, and Kintara Therapeutics (NASDAQ:KTRA) stock today.
Let us know what you think, please share your thoughts in the comments below.
